New regulations effective today will make it faster and easier for cutting-edge cancer treatments and personalised gene therapies to be made right where patients are treated.
Similar Posts
Breast implants – patient perception of risk research
Information for patients, public and healthcare professionals
MHRA statement on Pathways clinical trial
As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants.
MHRA approves tisotumab vedotin for the treatment of cervical cancer
As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used
Guidance: Pharmacovigilance following agreement of the Windsor Framework
Information on the implementation of changes to pharmacovigilance for medicines authorised in the UK following the agreement of the Windsor Framework.
Looking to our future: reflections on the strategic choices ahead for the MHRA
As part of developing its new five-year strategy, the MHRA is publishing a series of blogs on the challenges and opportunities ahead. In the first instalment, Chief Executive Lawrence Tallon reflects on the changing healthcare landscape, the regulator’s role, and the priorities shaping the agency’s future direction.
Class 4 Medicines Defect Notification: Viatris Products Ltd, Arixtra solution for injection, pre-filled syringes, EL(26)A/04
Viatris has received reports of brown discolouration and blockage in the needle of pre-filled syringes of Arixtra. This quality defect is related to oxidation of the syringe needle.